AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00017225
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02432911
Drug: CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
Trial: NCT03833336
Drug: Ferroglycine Sulfate
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
Trial: NCT03833336
Drug: Sucrosomial Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
Trial: NCT03963336
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous LMWH 1mg/kg/day for 2 weeks
Trial: NCT02214160
Drug: UX007
RxNorm normalized name: UX007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
Trial: NCT04113096
Drug: Dibenzyl trisulphide capsules
RxNorm normalized name: dibenzyl ether
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 6 months
Trial: NCT04113096
Drug: Stage IV Breast Cancer Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 6 months
Trial: NCT04113096
Drug: Stage IV: Colon Cancer Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 6 months
Trial: NCT04113096
Drug: Cervical Cancer Stage IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 6 months
Trial: NCT04113096
Drug: Cancer of the Prostate Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 6 months
Trial: NCT02191319
Drug: Viramune®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739141
Drug: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
Trial: NCT03754959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01571167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
Trial: NCT01784211
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01408849
Drug: Maytenus ilicifolia leaves infusion
RxNorm normalized name: Maytenus krukovii bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
Trial: NCT00004440
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02395978
Drug: PDC-1421 Capsule
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Trial: NCT02395978
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contained corn starch.
Trial: NCT00048412
Drug: CAMPATH 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238210
Drug: Atrovent®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03324035
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
Trial: NCT03287791
Drug: Finacea® (Azelaic Acid) Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical foam, brand product.
Trial: NCT00828243
Drug: Nutrient
RxNorm normalized name: Nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
Trial: NCT01568073
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5, 25 and 50 mg of BIA 9-1067 (once-daily)
Trial: NCT03811574
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
Trial: NCT02137863
Drug: 0.9 % NaCl
RxNorm normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
Trial: NCT02137863
Drug: 0.9 % NaCl
RxNorm normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Trial: NCT01381016
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
Trial: NCT00333008
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00121563
Drug: Thalidomide, Ibuprofen or Diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03083197
Drug: Doxycycline 7 days
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
Trial: NCT03083197
Drug: Doxycycline 3 days
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
Trial: NCT03083197
Drug: Azithromycin 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
Trial: NCT02886286
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-activated intrathecal bolus for incident pain
Trial: NCT00891436
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays each nostril every morning for 2 weeks
Trial: NCT02290613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets)
Trial: NCT02734849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as multiple doses
Trial: NCT00744224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo with saline infusion
Trial: NCT00744224
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 80 mg prednisolone with saline infusion
Trial: NCT00744224
Drug: Prednisolone and Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
Trial: NCT02616068
Drug: Transdermal Patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch 100 mg once a day for 7 days
Trial: NCT02616068
Drug: Placebo (for transdermal patch)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for transdermal patch 100 mg) once a day for 7 days
Trial: NCT06235424
Drug: Del Nido Cardioplegia Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
Trial: NCT06235424
Drug: HTK solution
RxNorm normalized name: Custodial HTK Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
Trial: NCT03098368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of rotigotine patch
Trial: NCT02699385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participants will receive placebo oral suspension thrice daily for up to 7 days.
Trial: NCT02539225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01086982
Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg, single dose
Trial: NCT01472003
Drug: ABT-806
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-806 will be administered by intravenous infusion.
Trial: NCT01472003
Drug: ABT-806i
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-806i will be administered by intravenous infusion.
Trial: NCT00928213
Drug: Low molecular weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-80 mg/day
Trial: NCT00928213
Drug: No Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment
Trial: NCT01071369
Drug: Xylocaine and Celestone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-particulate Celestone
Trial: NCT02098148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01934959
Drug: Bifico
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00942565
Drug: tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00942565
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03527836
Drug: Mixture brachial plexus block
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
Trial: NCT02576093
Drug: 0.1% WOL071-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Trial: NCT02576093
Drug: 0.3% WOL071-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Trial: NCT02576093
Drug: 1.0% WOL071-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Trial: NCT02576093
Drug: Placebo of WOL071-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Trial: NCT01960192
Drug: HD-MTX-Ara-C regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Trial: NCT01960192
Drug: FVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Trial: NCT00414856
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02544152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Trial: NCT01071291
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00598806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Trial: NCT05918614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Trial: NCT01808339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
Trial: NCT00348322
Drug: Systane Free Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238236
Drug: Alesion®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Syrup
Trial: NCT02730728
Drug: 20ml bolus of 0.5% ropivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic
Trial: NCT02730728
Drug: 0.2% Ropivicaine at 8 milliliter/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic
Trial: NCT02730728
Drug: 5ml bolus of 0.5% ropivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic
Trial: NCT01320475
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
Trial: NCT03148899
Drug: Placebo Intranasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
Trial: NCT01228149
Drug: Trabeculectomy with preoperative Diamox/DexaEDO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
Trial: NCT01228149
Drug: Trabeculectomy with preoperative Cosopt S treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
Trial: NCT01116635
Drug: doxorubicin, superabsorbent polymer microspheres, embolotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
Trial: NCT00158782
Drug: GW786034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
Trial: NCT00218569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02010567
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
Trial: NCT02010567
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
Trial: NCT03068624
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01105117
Drug: Flolan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per Prescribing Information
Trial: NCT03441516
Drug: Alfoatirin® Tab. + Aripezil® Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
Trial: NCT03441516
Drug: Aripezil® Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg Oral Tablet qd for 24 weeks
Trial: NCT01824420
Drug: Detrusitol 4mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infection, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bone Fracture, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Other Deformity, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Trial: NCT00797017
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
Trial: NCT02729870
Drug: Oral Glucose Gel
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
Trial: NCT00374192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00253890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 at bedtime
Trial: NCT01714960
Drug: MRZ-99030 eye drops 5mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01714960
Drug: MRZ-99030 eye drops 20mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01714960
Drug: Placebo to MRZ-99030 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03094481
Drug: Bupivacaine hydrogen chloride , epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine